Lexington, Mass. - Voyager Therapeutics, a leading biotechnology company, has announced a collaboration and license agreement with pharmaceutical giant Novartis. This deal, potentially worth over $1 billion, marks an exciting development for both companies. Under the agreement, Voyager will provide Novartis with a target-exclusive license to its Tracer capsids and other … [Read more...] about Voyager Therapeutics Announces Collaboration and License Agreement with Novartis
Gene therapies
AstraZeneca’s Acquisition of Gene Therapies Portfolio
AstraZeneca PLC (AZN) has recently announced a significant deal, acquiring a portfolio of gene therapies from Pfizer Inc. (PFE) for up to $1 billion. Set to close in the third quarter, this strategic move will provide AstraZeneca with a collection of early-stage gene therapies that specifically target rare diseases. This development holds immense potential as it has the … [Read more...] about AstraZeneca’s Acquisition of Gene Therapies Portfolio
